Panax GinsengvsTheacrine

Ginsenosides (Rb1, Rg1, Rg3, Re, and others) have diverse pharmacological actions. They modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol release under stress through glucocorticoid receptor modulation. Ginsenosides inhibit acetylcholinesterase (AChE), increasing acetylcholine levels in the hippocampus and enhancing muscarinic and nicotinic receptor function. They enhance nitric oxide production via endothelial nitric oxide synthase (eNOS) for cerebral vasodilation. Rb1 and Rg1 promote BDNF and NGF expression through activation of CREB and TrkB/TrkA signaling, supporting neuroplasticity. Rg1 specifically enhances hippocampal neurogenesis via the PI3K/Akt pathway and Wnt/β-catenin signaling, and improves spatial learning in animal models. Ginsenosides may also modulate GABA-A receptors and have antioxidant properties.

Theacrine activates dopamine receptors (D1 and D2 families) — likely as an indirect agonist via dopamine release or reuptake inhibition — and inhibits adenosine A1 and A2A receptors as an antagonist, similar to caffeine. Unlike caffeine, theacrine does not cause upregulation of adenosine receptors (A1R, A2AR) with chronic use, which is why tolerance does not develop; the structural difference (1,3,7-trimethyluric acid vs 1,3,7-trimethylxanthine) may alter receptor binding kinetics or downstream signaling. It modulates the adenosinergic and dopaminergic systems in a manner that maintains sensitivity over time — possibly through different metabolism (theacrine has a 16-20 hour half-life) or receptor interaction profiles. Theacrine provides anti-inflammatory effects through inhibition of NF-kB (reducing IKK activity and p65 nuclear translocation) and may have additional effects on phosphodiesterase inhibition, increasing cAMP.